FTC Affiliate Disclosure: This article may contain affiliate links. If you make a purchase through these links, a commission may be earned at no additional cost to you. Editorial content is not influenced by affiliate relationships. MedFoundationNC.org is an independent publication — not a medical practice, hospital, or healthcare provider. Read our full standards and disclosures.
Foundayo (orforglipron) is a prescription medication that requires evaluation by a licensed healthcare provider. This article is not medical advice. Consult your physician before starting, stopping, or changing any medication.
By MedFoundationNC.org Editorial Team | Last Updated: April 9, 2026
You've seen the headlines. On April 1, 2026, the FDA approved Foundayo — a once-daily Foundayo weight loss pill made by Eli Lilly — and within a week, Amazon announced same-day delivery in nearly 3,000 cities. The stock market reacted. The news cycle moved on. But if you're reading this, you're not looking for stock analysis or a Foundayo review built on press releases. You want to know whether the Foundayo Lilly pill could actually help you, what it costs, whether it's safe, and how to get it without overpaying.
That's what this article covers. Every claim below is attributed to Eli Lilly's published clinical trial data, the FDA's prescribing information, or verified third-party sources. Where information is evolving — especially around insurance coverage — we say so explicitly.
What Foundayo Actually Is — and Why It's Different
Foundayo is the brand name for orforglipron, a once-daily oral GLP-1 receptor agonist. It was developed by Eli Lilly and Company, the same manufacturer behind Zepbound and Mounjaro. The FDA approved it on April 1, 2026, for adults with obesity (BMI of 30 or higher) or adults who are overweight (BMI of 27 or higher) with at least one weight-related health condition such as high blood pressure, type 2 diabetes, or high cholesterol.
Here's what makes Foundayo different from every other GLP-1 medication currently on the market: it's a non-peptide small molecule. Every other GLP-1 drug — Wegovy, Ozempic, Zepbound, Mounjaro — is built on peptides, which are chains of amino acids that your stomach acid breaks down quickly. That's why most GLP-1 medications are injections, and why the Wegovy pill has to be taken on an empty stomach with strict fasting rules.
Foundayo doesn't have that problem. According to Eli Lilly's published prescribing information, it can be taken at any time of day, with or without food, and with no water restrictions. It also doesn't require refrigeration — it stores at room temperature. If you've been tracking the GLP-1 space, you know why that matters. For a breakdown of how all the current GLP-1 options work and where Foundayo fits into the picture, our guide to GLP-1 pills versus injections in 2026 covers the full picture.
Foundayo Clinical Trial Results: How Much Weight Loss?
The FDA's approval was based on Foundayo results from Eli Lilly's Phase 3 ATTAIN-1 trial, which enrolled more than 3,000 adults with obesity. So how much weight loss does Foundayo produce? According to the published ATTAIN trial data, participants taking the highest dose (Foundayo 17.2 mg, equivalent to the 36 mg investigational capsule) who completed the full 72 weeks of treatment lost an average of 27.3 pounds — or 12.4% of their starting body weight — compared to 2.2 pounds (0.9%) for those on placebo.
When you look at the treatment-regimen analysis — which includes all participants regardless of whether they completed the full course — the numbers come in at 25.0 pounds (11.2%) versus 5.3 pounds (2.1%) with placebo. That's the more conservative number, and it's still meaningful.
Beyond weight loss, Eli Lilly reported that Foundayo also led to reductions in waist circumference, non-HDL cholesterol, triglycerides, and systolic blood pressure across all dose levels tested. According to published FDA review documents, most participants began seeing results within the first four weeks of daily use, though it can take several months of dose escalation to reach maximum effect.
An important note on context: these results are from Foundayo's own clinical trials. No head-to-head trial has compared Foundayo to the Wegovy pill at their FDA-approved obesity doses. Cross-trial comparisons suggest the Wegovy pill may produce slightly more weight loss (approximately 17% in published trials), while injectable GLP-1 medications like Zepbound show approximately 21% average body-weight reduction. We break down these comparisons in detail in our Foundayo vs Wegovy vs Zepbound analysis.
Foundayo Dosing: How the Titration Schedule Works
According to the FDA-approved prescribing information, Foundayo comes in six dose strengths: 0.8 mg, 2.5 mg, 5.5 mg, 9 mg, 14.5 mg, and 17.2 mg. Everyone starts at the lowest dose and works up gradually. The schedule looks like this:
You start at 0.8 mg once daily. After at least 30 days, your prescriber increases the dose to 2.5 mg. After another 30 days at that level, you move to 5.5 mg. From there, your prescriber may continue increasing — to 9 mg, 14.5 mg, or 17.2 mg — based on how your body responds and how well you tolerate each dose. Each step requires a minimum of 30 days before moving up.
This gradual approach is designed to minimize gastrointestinal side effects, which are most common when starting the medication and during dose increases. If you miss seven or more consecutive doses, the prescribing information states that your provider may need to restart you at a lower dose and work back up. For a more detailed look at what to expect as your body adjusts, including the side effect profile at each dose level, see our Foundayo side effects and safety guide.
Foundayo Cost in 2026: What You'll Actually Pay
Foundayo price is one of the most searched questions about this medication, and the answer depends entirely on your Foundayo insurance situation. Here's what Eli Lilly has published as of April 2026:
If you have commercial insurance that covers Foundayo, you may pay as little as $25 per month using the Foundayo Savings Card. Eligibility requires a prescription for an FDA-approved use, commercial drug insurance that covers Foundayo, U.S. residency, and you must be 18 or older. Government insurance beneficiaries — including Medicare, Medicaid, VA, TRICARE, and DoD — are excluded from this savings card program.
If you're paying out of pocket (self-pay), Eli Lilly's published pricing through LillyDirect starts at $149 per month for the 0.8 mg starter dose, $199 per month for 2.5 mg, and $299 per month for 5.5 mg and higher doses. The two highest doses (14.5 mg and 17.2 mg) are priced at $299 through Lilly's Journey Program, but if a prescription isn't refilled within 45 days, the price reverts to $349 per month.
Foundayo Medicare coverage: Eli Lilly has stated that eligible Medicare Part D beneficiaries may be able to access Foundayo for approximately $50 per month beginning as early as July 1, 2026. This is connected to the CMS BALANCE model, which is expanding Medicare coverage for obesity medications. Coverage details and eligibility should be verified directly with your plan, as this is a new and evolving program.
Foundayo Amazon Pharmacy pricing, announced April 9, 2026, starts as low as $1 per day ($25/month) with insurance and $5 per day ($149/month) for cash-pay customers. According to Amazon's press release, manufacturer-sponsored coupons are applied automatically before checkout. For patients looking to buy Foundayo through Amazon, no additional membership is required beyond a valid prescription.
The savings card program expires December 31, 2026, and Eli Lilly reserves the right to change terms at any time. Coverage varies by insurer — as of April 2026, some commercial plans have begun covering Foundayo, but coverage for weight loss medications remains inconsistent across the industry. For readers evaluating the full range of GLP-1 pricing options — including telehealth-based compounded alternatives at different price points — our Direct Meds review and TrimRx evaluation cover what those programs cost and how they differ.
How to Get Foundayo: Availability and Access
According to Eli Lilly, Foundayo became available through LillyDirect starting April 6, 2026, with broad retail pharmacy availability rolling out shortly after. As of April 9, 2026, Amazon Pharmacy has also begun stocking and delivering Foundayo, with same-day delivery available in nearly 3,000 U.S. cities and towns — a number Amazon says will expand to approximately 4,500 by the end of 2026.
Amazon is also placing Foundayo at in-office kiosks inside select One Medical clinic locations, where patients can pick up the medication within minutes of a medical appointment. These kiosks are currently operating in California, with plans to expand to additional states pending regulatory approval. No One Medical membership is required to use the kiosks.
The process starts with a Foundayo prescription from a licensed healthcare provider. You can ask your doctor to send the prescription to LillyDirect Pharmacy (NPI: 1912889320), or you can fill it through Amazon Pharmacy, a retail pharmacy, or a connected telehealth provider. Lilly's prescribing partners include WeightWatchers and other telehealth platforms. If you're wondering where to buy Foundayo, those are your current channels — there is no over-the-counter option and no legitimate way to buy Foundayo online without a prescription.
Who Foundayo Is For — and Who It Isn't For
According to the FDA-approved labeling, Foundayo eligibility requires a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related comorbid condition — that's the Foundayo BMI requirement. It's prescribed alongside a reduced-calorie diet and increased physical activity. If you don't meet these criteria, a prescriber won't write the Foundayo prescription. For those exploring Foundayo without insurance, the self-pay pricing through LillyDirect starts at $149 per month and doesn't require coverage.
Foundayo is contraindicated — meaning it should not be taken — by patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2). This carries a boxed warning on the prescribing information.
The prescribing information also lists several precautions. Patients taking oral hormonal contraceptives should discuss alternatives with their provider, because Foundayo's delayed gastric emptying may reduce absorption of oral birth control pills. The prescribing information recommends switching to a non-oral method or adding a barrier method for 30 days after starting the medication and after each dose increase. Patients on simvastatin should not exceed 20 mg daily while taking Foundayo. Strong CYP3A4 inhibitors that also inhibit OATP1B should be avoided, and the maximum Foundayo dose is capped at 9 mg when taken with a strong CYP3A4 inhibitor.
If you're scheduled for surgery or any procedure involving anesthesia, tell your medical team that you're taking Foundayo. Like other GLP-1 medications, it slows gastric emptying, which can increase the risk of aspiration during sedation. The prescribing information also flags monitoring considerations for pancreatitis, gallbladder disease, and hypoglycemia (particularly when combined with insulin or sulfonylureas).
Foundayo has not been studied in pregnant or breastfeeding women and is not recommended during pregnancy. A pregnancy exposure registry is available through Eli Lilly (1-800-545-5979).
How Foundayo Fits into the GLP-1 Market in 2026
As of April 2026, the GLP-1 weight loss market includes injectable options (Wegovy, Zepbound), two FDA-approved oral pills (the Wegovy pill and Foundayo), and a growing number of telehealth platforms offering compounded GLP-1 formulations that operate under different regulatory frameworks.
Foundayo is FDA-approved — meaning it went through the full clinical trial and FDA review process. Compounded GLP-1 medications, which are available through telehealth platforms like MEDVi, TrimRx, and Direct Meds, are not FDA-approved as finished products. They combine FDA-approved active ingredients in custom formulations prepared by compounding pharmacies. These are different categories with different regulatory standards, different pricing structures, and different levels of published clinical data. For a detailed evaluation of one of the most prominent compounded GLP-1 platforms — including the FDA warning letter, consumer review data, and billing practices — see our MEDVi 2026 fact-check.
For readers who haven't tried any GLP-1 medication before: Foundayo represents a lower-cost, lower-barrier entry point into the FDA-approved GLP-1 market. For those currently on injectable GLP-1 medications: Eli Lilly's published Phase 3 data shows that patients who switched from injectable GLP-1 treatment to Foundayo were able to maintain their weight loss — positioning it as a potential step-down maintenance option. For readers already exploring compounded alternatives through telehealth: it's worth understanding how Foundayo's pricing, clinical evidence, and FDA approval status compare to what you're currently considering.
Eli Lilly has also submitted Foundayo for regulatory approval in more than 40 countries and is studying the drug for additional indications including type 2 diabetes, obstructive sleep apnea, hypertension, osteoarthritis knee pain, and stress urinary incontinence. The company also has retatrutide — a next-generation triple-agonist — in late-stage clinical trials, which has shown greater weight loss in published trials than any other GLP-1 medication currently available.
The Bottom Line
Foundayo is real, it's FDA-approved, and it's available now. The clinical data shows meaningful weight loss — an average of 12.4% body weight at the highest dose over 72 weeks — with a side effect profile consistent with the GLP-1 drug class. The convenience factor is significant: no injections, no fasting requirements, no refrigeration, any time of day. Pricing starts at $149 per month out of pocket and may be as low as $25 with commercial insurance.
It's not a miracle. It produces less weight loss on average than injectable GLP-1 options. Insurance coverage is still catching up. And like every GLP-1 medication, it requires ongoing use to maintain results — when people stop taking it, weight tends to return. If you're already on an injectable GLP-1 and finding that progress has stalled, our guide to what to do when GLP-1 injections stop working covers the most common causes and next steps. But for people who haven't started GLP-1 treatment because of cost, needles, or complexity, Foundayo removes several of those barriers simultaneously.
Talk to your doctor. If you qualify, the medication is accessible through multiple channels starting now — and our guide to getting Foundayo through telehealth walks through the process step by step. If insurance is a concern, our Foundayo insurance coverage guide breaks down what's covered, what isn't, and how to appeal a denial. If you have type 2 diabetes alongside weight management goals, our Foundayo and type 2 diabetes guide covers the specific clinical data for your situation. If you don't qualify or if the pricing doesn't work for your situation, the GLP-1 market has more options than it did six months ago — and our guides to GLP-1 pills vs injections, Foundayo side effects, and how Foundayo compares to Wegovy and Zepbound can help you evaluate what fits.
Published April 9, 2026. MedFoundationNC.org Editorial Team.
Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Foundayo (orforglipron) is a prescription medication manufactured by Eli Lilly and Company. All clinical claims in this article are attributed to Eli Lilly's published trial data, FDA labeling, or cited third-party sources. Individual results vary. Consult a licensed healthcare provider before starting any medication. MedFoundationNC.org is an independent editorial publication — not a medical practice, hospital, or healthcare provider.
FDA/Regulatory Disclaimer: Foundayo is an FDA-approved prescription medication. It is not a supplement. The FDA approved Foundayo on April 1, 2026, under the Commissioner's National Priority Voucher program. Pricing, insurance coverage, availability, and savings program terms referenced in this article are based on published information from Eli Lilly and Company as of April 2026 and are subject to change. Verify current terms directly with Eli Lilly, your pharmacy, and your insurance provider before making enrollment decisions.